Gries Financial LLC Gilead Sciences, Inc. Transaction History

Gries Financial LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Jun 21, 2023	SELL	$77.31 - $88.08 $3.18 Million - $3.63 Million	-41,184 Reduced 84.12%	7,776 $645,000
Q4 2022 Jan 10, 2023	BUY	$62.32 - $89.47 $965,274 - $1.39 Million	15,489 Added 46.28%	48,960 $4.2 Million
Q3 2022 Oct 31, 2022	BUY	$59.54 - $68.01 $82,284 - $93,989	1,382 Added 4.31%	33,471 $2.07 Million
Q2 2022 Aug 16, 2022	BUY	$57.72 - $65.01 $35,959 - $40,501	623 Added 1.98%	32,089 $1.98 Million
Q1 2022 Apr 29, 2022	BUY	$57.92 - $72.58 $590,668 - $740,170	10,198 Added 47.95%	31,466 $1.87 Million
Q4 2021 Feb 02, 2022	SELL	$64.88 - $73.64 $1.43 Million - $1.62 Million	-22,003 Reduced 50.85%	21,268 $1.54 Million
Q3 2021 Nov 12, 2021	SELL	$67.69 - $73.03 $319,632 - $344,847	-4,722 Reduced 9.84%	43,271 $3.02 Million
Q2 2021 Aug 09, 2021	BUY	$63.47 - $69.35 $1.19 Million - $1.3 Million	18,676 Added 63.7%	47,993 $3.32 Million
Q1 2021 May 17, 2021	BUY	$60.0 - $68.46 $1.76 Million - $2.01 Million	29,317 New	29,317 $2.02 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Gries Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Gries Financial LLC with notifications on news.